Nautilus Biotechnology (NAUT) Free Cash Flow (2020 - 2026)

Nautilus Biotechnology has disclosed Free Cash Flow across 7 years of filings, most recently posting -$13.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$13.6 million, up 3.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.4 million (up 12.11% YoY), and the FY2025 annual result was -$52.0 million, up 15.17% from the prior year.
• Free Cash Flow came in at -$13.6 million for Q1 2026 at Nautilus Biotechnology, down from -$12.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$10.5 million in Q3 2022 to a low of -$16.9 million in Q1 2024.
• The 5-year median for Free Cash Flow is -$13.7 million (2025), against an average of -$13.5 million.
• Peak annual rise in Free Cash Flow reached 27.13% in 2022, while the deepest fall reached 90.29% in 2022.
• Nautilus Biotechnology's Free Cash Flow stood at -$10.6 million in 2022, then slumped by 34.95% to -$14.3 million in 2023, then slipped by 1.75% to -$14.6 million in 2024, then climbed by 13.35% to -$12.6 million in 2025, then slipped by 7.85% to -$13.6 million in 2026.
• The last three Free Cash Flow figures came in at -$13.6 million (Q1 2026), -$12.6 million (Q4 2025), and -$11.5 million (Q3 2025), per Business Quant data.